pyrimidinyl furanyl oxazolyl isoxazolyl triazolyl tetrazolyl pyrazolyl thienyl etc u201c cycloalkyl u201d means a saturated or partially unsaturated monocyclic fused bicyclic or bridged polycyclic ring assembly containing the number of ring atoms indicated for example c 3 10 cycloalkyl includes cyclopropyl cyclobutyl cyclopentyl cyclohexyl etc u201c heterocycloalkyl u201d means cycloalkyl as defined in this application provided that one or more of the ring carbons indicated are replaced by a moiety selected from u2014 o u2014 u2014 n u2550 u2014 nr u2014 u2014 c o u2014 u2014 s u2014 u2014 s o u2014 or u2014 s o 2 u2014 wherein r is hydrogen c 1 4 alkyl or a nitrogen protecting group for example c 3 8 heterocycloalkyl as used in this application to describe compounds of the invention includes morpholino pyrrolidinyl pyrrolidinyl 2 one piperazinyl piperidinyl piperidinylone 1 4 dioxa 8 aza spiro 4 5 dec 8 yl etc u201c halogen u201d or halo preferably represents chloro or fluoro but may also be bromo or iodo u201c treat u201d u201c treating u201d and u201c treatment u201d refer to a method of alleviating or abating a disease and or its attendant symptoms the present invention provides compounds compositions and methods for the treatment of kinase related disease particularly iptkb related diseases for example autoimmune diseases particularly b cell associated diseases are related to iptkb for example rheumatoid arthritis systemic lupus erythematosus sle immune thrombocytopenic purpura itp and hemolytic anemia in one embodiment with reference to compounds of formula i n is selected from 1 and 2 m is selected from 0 1 and 2 a can have.